Response and outcomes of maintenance avelumab after platinum-based chemotherapy (PBC) in patients with advanced urothelial carcinoma (aUC): ‘real world’ experience
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Response and outcomes of maintenance avelumab after platinum-based chemotherapy (PBC) in patients with advanced urothelial carcinoma (aUC): ‘real world’ experience
Authors
Keywords
-
Journal
Clinical Genitourinary Cancer
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-06-21
DOI
10.1016/j.clgc.2023.06.008
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Baseline characteristics from a retrospective, observational, US-based, multicenter, real-world (RW) study of avelumab first-line maintenance (1LM) in locally advanced/metastatic urothelial carcinoma (la/mUC) (PATRIOT-II).
- (2023) Petros Grivas et al. JOURNAL OF CLINICAL ONCOLOGY
- READY: Real-world data from an Italian compassionate use program of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC).
- (2023) Lorenzo Antonuzzo et al. JOURNAL OF CLINICAL ONCOLOGY
- Response and outcomes of maintenance avelumab after platinum-based chemotherapy (PBC) in patients (pts) with advanced urothelial carcinoma (aUC): "Real world" experience.
- (2023) Dimitra Rafailia Bakaloudi et al. JOURNAL OF CLINICAL ONCOLOGY
- Uptake of maintenance immunotherapy and changes in upstream treatment selection in patients with advanced urothelial cancer (aUC).
- (2023) Ronac Mamtani et al. JOURNAL OF CLINICAL ONCOLOGY
- Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up
- (2023) Thomas Powles et al. JOURNAL OF CLINICAL ONCOLOGY
- Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy.
- (2023) Srikala S. Sridhar et al. JOURNAL OF CLINICAL ONCOLOGY
- Full analysis from AVENANCE: A real-world study of avelumab first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC).
- (2023) Philippe Barthelemy et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized, double blind, biomarker selected, phase II clinical trial of maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS rucaparib arm.
- (2022) Simon J. Crabb et al. JOURNAL OF CLINICAL ONCOLOGY
- Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
- (2022) Dimitrios Makrakis et al. Clinical Genitourinary Cancer
- MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer (mUC) (Alliance A032001).
- (2022) Shilpa Gupta et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomised, double blind, phase II clinical trial of maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS cabozantinib comparison.
- (2022) Robert J. Jones et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma
- (2022) Rafee Talukder et al. Clinical Genitourinary Cancer
- TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma
- (2022) Elodie Coquan et al. BMC CANCER
- Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
- (2022) Dimitrios Makrakis et al. Clinical Genitourinary Cancer
- Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes
- (2021) Stepan M. Esagian et al. BJU INTERNATIONAL
- Association of prior local therapy and outcomes with programmed‐death ligand‐1 inhibitors in advanced urothelial cancer
- (2021) Dimitrios Makrakis et al. BJU INTERNATIONAL
- Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin
- (2021) Rafee Talukder et al. Clinical Genitourinary Cancer
- Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial
- (2021) Thomas Powles et al. NATURE MEDICINE
- Histologic Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study
- (2020) Natalie J. Miller et al. JOURNAL OF UROLOGY
- Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer
- (2020) Matthew D. Galsky et al. JOURNAL OF CLINICAL ONCOLOGY
- Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
- (2020) Thomas Powles et al. NEW ENGLAND JOURNAL OF MEDICINE
- The REDCap consortium: Building an international community of software platform partners
- (2019) Paul A. Harris et al. JOURNAL OF BIOMEDICAL INFORMATICS
- Impact of performance status on treatment outcomes: A real‐world study of advanced urothelial cancer treated with immune checkpoint inhibitors
- (2019) Ali Raza Khaki et al. CANCER
- Survival Rates and Health Care Costs for Patients With Advanced Bladder Cancer Treated and Untreated With Chemotherapy
- (2018) Kyle Flannery et al. Clinical Genitourinary Cancer
- Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
- (2017) Philippe E. Spiess et al. Journal of the National Comprehensive Cancer Network
- World Medical Association Declaration of Helsinki
- (2013) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support
- (2008) Paul A. Harris et al. JOURNAL OF BIOMEDICAL INFORMATICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started